0

Close
 
Upcoming Allied Market Research
2023
Glp-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market

by Product (Victoza, Ozempic, Trulicity, Bydureon, Saxenda, Others) and by End User (Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A10497
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Glp-1 Receptor Agonist Market

Request Now !

GLP-1 stands for glucagon-like peptide, a type of hormone known as an incretin hormone that is lower than normal in people with type 2 diabetes. GLP-1 receptor agonists belong to a class of medications known as incretin mimetics that help the pancreas to release the optimal amount of insulin, a hormone that transports glucose (sugar) to tissues in the body where it can be used for energy.The specific role of these drugs is to help lower blood glucose levels specifically, hemoglobin A1C and to aid in weight loss. Research has shown that GLP-1 receptor agonists can have other health benefits, including positive effects on blood pressure, cholesterol levels, and beta-cell function. These injectable drugs are prescribed along with oral diabetes medicines and insulin therapy. As such, they are not regarded as first-line treatment in diabetes, but they can be a valuable part of the overall diabetes management plan.

GLP-1-Receptor-Agonist

COVID-19 scenarioanalysis

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak, from supporting the development of vaccines to scheduling medicines supply chain challenges. Around 115 vaccine candidates and other 155 molecules are in the R&D pipeline. Furthermore, the commonly used drugs, such as hydroxychloroquine, have observed huge boost in demand for the management of COVID-19. In addition, increase has been experienced in the demand for COVID-19 management drugs, which is expected to offer potential opportunity for manufacturers of drugs, as many developed countries are short of these drugs. Owing to the growing demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors:market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the marketgrowth includes the advancement in the GLP-1 receptor agonist such that it could meet the market demand amalgamated with the stronger product pipeline. This would help the market to gain traction during the forecast period. There has been an increase in the number of diabetic patients and other disorders such as obesity that may cause diabetes, which would propel the growth of the market in the coming years. However, the product failure may hinder the growth of the market.

Increase in the number of product approvals

Rise in the number of product approvals would help the market flourish during the forecast period. For instance, in September 2019, the FDA approved oral semaglutide, the first noninjectable GLP-1 receptor agonist for the treatment of type 2 diabetes.Increase in the number of product approvals that assists with the cure of the diabetes would help the market to gain traction in the coming years.

In September 2017, Lupin Ltd., India’s second largest pharmaceutical company, was seeking to enhance its diabetes drugs offering in the domestic market by bringing in a new class of drugs through the in-licensing route.Under in-licensing, a company gets a license to market a product of another company in one or more geographies. Lupin’s current diabetes product portfolio includes different classes of drugs such as oral hypoglycemic agents (OHAs), insulins and novel drugs such as sodium glucose co-transporter-2 (SGLT-2) inhibitor drug empagliflozin and dipeptidylpeptidase-4 (DPP-4) inhibitor drug linagliptin.

Surge in number of mergers and acquisitions

Increase in the number of mergers and acquisitions is anticipated to help the marketboost in the coming years. For instance, in November 2020, Emisphere Technologies, Inc. entered into a definitive agreement with Novo Nordisk A/S. Similarly, Novo Nordisk will acquire Emisphere for $1.35 billion in cash. This would allow Novo Nordisk’s oral semaglutide, GLP-1 receptor agonist to be distributed in a bigger distribution channel and hence would help the market propel over the coming years.

Key benefits of the report:

  • This study presents the analytical depiction of the global GLP-1 receptor agonistindustry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global GLP-1 receptor agonistmarket share.
  • The current market is quantitatively analyzed to highlight the global GLP-1 receptor agonistmarket growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the GLP-1 receptor agonistmarket.
  • The report provides a detailed global GLP-1 receptor agonistmarket analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the GLP-1 receptor agonistmarket research report:

  • Which are the leading players active in the GLP-1 receptor agonistmarket?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in tasking further strategic steps?

 GLP-1 Receptor Agonist Market Report Highlights

Aspects Details
By Product
  • Victoza
  • Ozempic
  • Trulicity
  • Bydureon
  • Saxenda
  • Others
By End User
  • Hospital Pharmacies
  • Retail Pharmacies
  • Diabetes Clinics
  • Online Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Eli Lilly and Company, Hanmi Pharmaceutical, Novo Nordisk A/S,, PegBio, Pfizer, Jiangsu Hengrui Medicine Co., Innovent Biologics, Amgen, Sanofi,, AstraZeneca,
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: GLP-1 RECEPTOR AGONIST MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Victoza

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Ozempic

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Trulicity

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Bydureon

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Saxenda

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Others

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: GLP-1 RECEPTOR AGONIST MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospital Pharmacies

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Retail Pharmacies

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Diabetes Clinics

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Online Pharmacies

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: GLP-1 RECEPTOR AGONIST MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Glp-1 Receptor Agonist Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Glp-1 Receptor Agonist Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Glp-1 Receptor Agonist Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Glp-1 Receptor Agonist Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Glp-1 Receptor Agonist Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Glp-1 Receptor Agonist Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Glp-1 Receptor Agonist Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Glp-1 Receptor Agonist Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Glp-1 Receptor Agonist Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Glp-1 Receptor Agonist Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Glp-1 Receptor Agonist Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Glp-1 Receptor Agonist Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Glp-1 Receptor Agonist Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Glp-1 Receptor Agonist Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Glp-1 Receptor Agonist Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Glp-1 Receptor Agonist Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Glp-1 Receptor Agonist Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Glp-1 Receptor Agonist Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Glp-1 Receptor Agonist Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Glp-1 Receptor Agonist Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Glp-1 Receptor Agonist Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Glp-1 Receptor Agonist Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Glp-1 Receptor Agonist Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Glp-1 Receptor Agonist Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Glp-1 Receptor Agonist Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. AstraZeneca,

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novo Nordisk A/S,

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Sanofi,

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Eli Lilly And Company

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Innovent Biologics

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Amgen

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Pfizer

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. PegBio

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Hanmi Pharmaceutical

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Jiangsu Hengrui Medicine Co.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL GLP-1 RECEPTOR AGONIST MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR VICTOZA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR OZEMPIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR TRULICITY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR BYDUREON, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR SAXENDA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR DIABETES CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA GLP-1 RECEPTOR AGONIST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. U.S. GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 18. U.S. GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. CANADA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 20. CANADA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. MEXICO GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE GLP-1 RECEPTOR AGONIST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. FRANCE GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. GERMANY GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. GERMANY GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. ITALY GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. ITALY GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. SPAIN GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. UK GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 35. UK GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. RUSSIA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. RUSSIA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. REST OF EUROPE GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 39. REST OF EUROPE GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. CHINA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. CHINA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. JAPAN GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. JAPAN GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. INDIA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. INDIA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. SOUTH KOREA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. SOUTH KOREA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. AUSTRALIA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. AUSTRALIA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. THAILAND GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. THAILAND GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. MALAYSIA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. MALAYSIA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. INDONESIA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 58. INDONESIA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA GLP-1 RECEPTOR AGONIST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 62. LAMEA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. LAMEA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. BRAZIL GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. BRAZIL GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH AFRICA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH AFRICA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. SAUDI ARABIA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. SAUDI ARABIA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. UAE GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. UAE GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. ARGENTINA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 73. ARGENTINA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. REST OF LAMEA GLP-1 RECEPTOR AGONIST, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 75. REST OF LAMEA GLP-1 RECEPTOR AGONIST, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. ASTRAZENECA,: KEY EXECUTIVES
  • TABLE 77. ASTRAZENECA,: COMPANY SNAPSHOT
  • TABLE 78. ASTRAZENECA,: OPERATING SEGMENTS
  • TABLE 79. ASTRAZENECA,: PRODUCT PORTFOLIO
  • TABLE 80. ASTRAZENECA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. NOVO NORDISK A/S,: KEY EXECUTIVES
  • TABLE 82. NOVO NORDISK A/S,: COMPANY SNAPSHOT
  • TABLE 83. NOVO NORDISK A/S,: OPERATING SEGMENTS
  • TABLE 84. NOVO NORDISK A/S,: PRODUCT PORTFOLIO
  • TABLE 85. NOVO NORDISK A/S,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. SANOFI,: KEY EXECUTIVES
  • TABLE 87. SANOFI,: COMPANY SNAPSHOT
  • TABLE 88. SANOFI,: OPERATING SEGMENTS
  • TABLE 89. SANOFI,: PRODUCT PORTFOLIO
  • TABLE 90. SANOFI,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 92. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 93. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 94. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 95. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. INNOVENT BIOLOGICS: KEY EXECUTIVES
  • TABLE 97. INNOVENT BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 98. INNOVENT BIOLOGICS: OPERATING SEGMENTS
  • TABLE 99. INNOVENT BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 100. INNOVENT BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. AMGEN: KEY EXECUTIVES
  • TABLE 102. AMGEN: COMPANY SNAPSHOT
  • TABLE 103. AMGEN: OPERATING SEGMENTS
  • TABLE 104. AMGEN: PRODUCT PORTFOLIO
  • TABLE 105. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. PFIZER: KEY EXECUTIVES
  • TABLE 107. PFIZER: COMPANY SNAPSHOT
  • TABLE 108. PFIZER: OPERATING SEGMENTS
  • TABLE 109. PFIZER: PRODUCT PORTFOLIO
  • TABLE 110. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. PEGBIO: KEY EXECUTIVES
  • TABLE 112. PEGBIO: COMPANY SNAPSHOT
  • TABLE 113. PEGBIO: OPERATING SEGMENTS
  • TABLE 114. PEGBIO: PRODUCT PORTFOLIO
  • TABLE 115. PEGBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. HANMI PHARMACEUTICAL: KEY EXECUTIVES
  • TABLE 117. HANMI PHARMACEUTICAL: COMPANY SNAPSHOT
  • TABLE 118. HANMI PHARMACEUTICAL: OPERATING SEGMENTS
  • TABLE 119. HANMI PHARMACEUTICAL: PRODUCT PORTFOLIO
  • TABLE 120. HANMI PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. JIANGSU HENGRUI MEDICINE CO.: KEY EXECUTIVES
  • TABLE 122. JIANGSU HENGRUI MEDICINE CO.: COMPANY SNAPSHOT
  • TABLE 123. JIANGSU HENGRUI MEDICINE CO.: OPERATING SEGMENTS
  • TABLE 124. JIANGSU HENGRUI MEDICINE CO.: PRODUCT PORTFOLIO
  • TABLE 125. JIANGSU HENGRUI MEDICINE CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION
  • FIGURE 2. GLOBAL GLP-1 RECEPTOR AGONIST MARKET
  • FIGURE 3. SEGMENTATION GLP-1 RECEPTOR AGONIST MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN GLP-1 RECEPTOR AGONIST MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGLP-1 RECEPTOR AGONIST MARKET
  • FIGURE 11. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. GLP-1 RECEPTOR AGONIST MARKET FOR VICTOZA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. GLP-1 RECEPTOR AGONIST MARKET FOR OZEMPIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. GLP-1 RECEPTOR AGONIST MARKET FOR TRULICITY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. GLP-1 RECEPTOR AGONIST MARKET FOR BYDUREON, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. GLP-1 RECEPTOR AGONIST MARKET FOR SAXENDA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. GLP-1 RECEPTOR AGONIST MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION, BY BY END USER
  • FIGURE 19. GLP-1 RECEPTOR AGONIST MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. GLP-1 RECEPTOR AGONIST MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. GLP-1 RECEPTOR AGONIST MARKET FOR DIABETES CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. GLP-1 RECEPTOR AGONIST MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: GLP-1 RECEPTOR AGONIST MARKET
  • FIGURE 29. Top player positioning, 2022
  • FIGURE 30. ASTRAZENECA,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. ASTRAZENECA,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. ASTRAZENECA,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. NOVO NORDISK A/S,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. NOVO NORDISK A/S,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. NOVO NORDISK A/S,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. SANOFI,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. SANOFI,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. SANOFI,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ELI LILLY AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. INNOVENT BIOLOGICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. INNOVENT BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. INNOVENT BIOLOGICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. AMGEN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. AMGEN: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. AMGEN: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. PFIZER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. PFIZER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. PFIZER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. PEGBIO: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. PEGBIO: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. PEGBIO: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. HANMI PHARMACEUTICAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. HANMI PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. HANMI PHARMACEUTICAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. JIANGSU HENGRUI MEDICINE CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. JIANGSU HENGRUI MEDICINE CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. JIANGSU HENGRUI MEDICINE CO.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Glp-1 Receptor Agonist Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers